Results 91 to 100 of about 2,065,768 (386)

What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC) [PDF]

, 2018
In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells
Manicone, M., Mariotta, S., Pezzuto, A., Ricci, A., Rossi, Elisabetta, Scaini, M. C., Zamarchi, R.   +6 more
core   +1 more source

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset

Cancers, 2019
The release of circulating tumor cells (CTCs) into vasculature is an early event in the metastatic process. The analysis of CTCs in patients has recently received widespread attention because of its clinical implications, particularly for precision ...
Chiara Agnoletto, Fabio Corrà, Linda Minotti, F. Baldassari, Francesca Crudele, W. Cook, Gianpiero di Leva, A. d’Adamo, P. Gasparini, S. Volinia   +9 more
semanticscholar   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up

BMC Cancer, 2020
Background While circulating tumor cells may serve as minimally invasive cancer markers for bladder cancers, the relationship between primary bladder cancers and circulating tumor cells in terms of somatic mutations is largely unknown.
Tae-Min Kim, Jin-seon Yoo, Hyong Woo Moon, Kyung Jae Hur, Jin Bong Choi, Sung-Hoo Hong, Ji Youl Lee, U-Syn Ha   +7 more
doaj   +1 more source

A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. [PDF]

, 2007
Canonical Wnt signaling is an osteo-inductive signal that promotes bone repair through acceleration of osteogenic differentiation by progenitors. Dkk-1 is a secreted inhibitor of canonical Wnt signaling and thus inhibits osteogenesis.
Angela Smolarz, Carl Gregory, Darwin Prockop, Edwin Horwitz, Jacob Reiser, Najat Daw, Narae Lee, Odile David, Robert Kutner, Scott Olson   +9 more
core   +3 more sources

In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma

Science Translational Medicine, 2019
Noninvasive label-free photoacoustic detection of circulating tumor cells was demonstrated directly in the bloodstream of patients with melanoma. Zooming in on tumor cells Circulating tumor cells in patients’ blood can offer insight into the underlying ...
E. Galanzha, Y. Menyaev, Aayire C. Yadem, M. Sarimollaoglu, Mazen A. Juratli, D. Nedosekin, S. Foster, Azemat Jamshidi-Parsian, E. Siegel, I. Makhoul, L. Hutchins, J. Suen, V. Zharov   +12 more
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Frontiers in Oncology
BackgroundThe heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib.
Aliki Ntzifa, Theodoros Marras, Galatea Kallergi, Athanasios Kotsakis, Vasilis Georgoulias, Evi Lianidou   +5 more
doaj   +1 more source

Circulating Tumor Cells and PET [PDF]

Journal of Nuclear Medicine, 2011
Understanding the distinct molecular features of solid tumors provides the opportunity to develop more targeted and effective therapies. The evaluation and monitoring of these therapies require sophisticated laboratory and imaging technologies to detect potential benefit not necessarily translating into significant changes in tumor size.
Jian Q, Yu, Massimo, Cristofanilli
openaire   +2 more sources

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source